Skip to the page

Data / Drug companies / Aurolife Pharma, LLC

Aurolife Pharma, LLC: 70 products in the FDA NDC directory, labeler code 13107

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Aurolife Pharma, LLC (labeler code 13107) lists 70 products in the FDA National Drug Code Directory, covering 22 finished drugs by generic name. By type: 70 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 14, 2026.

The request: Watch Aurolife Pharma, LLC (FDA labeler code 13107): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
13107
Products in commercial distribution
70
Packages
235
Finished drugs by generic name
22
Prescription products
70
Over the counter products
0
Controlled substance products
Schedule II 37, Schedule III 4, Schedule IV 12
Flagged as original packager
65 of 65 products that carry the flag
Started marketing in the last 12 months
3
Products with a marketing end date set
3
Earliest marketing start
July 17, 1987
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)70100%

Products by type

TypeProductsShare
Prescription drugs70100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet5375.7%
Tablet, film coated912.9%
Solution34.3%
Capsule34.3%
Aerosol, metered22.9%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Beclomethasone Dipropionate13107-231Aerosol, meteredGeneric drugs (ANDA)September 14, 2026
Beclomethasone Dipropionate13107-230Aerosol, meteredGeneric drugs (ANDA)September 14, 2026
Phentermine hydrochloride13107-061TabletGeneric drugs (ANDA)April 10, 2026
Clorazepate dipotassium13107-284TabletGeneric drugs (ANDA)September 23, 2023
Clorazepate dipotassium13107-283TabletGeneric drugs (ANDA)September 23, 2023
Clorazepate dipotassium13107-282TabletGeneric drugs (ANDA)September 23, 2023
Glycopyrrolate13107-015TabletGeneric drugs (ANDA)February 28, 2023
Glycopyrrolate13107-014TabletGeneric drugs (ANDA)February 28, 2023
Diclofenac Sodium13107-269SolutionGeneric drugs (ANDA)February 3, 2023
Lorazepam13107-085TabletGeneric drugs (ANDA)February 1, 2021
Lorazepam13107-084TabletGeneric drugs (ANDA)February 1, 2021
Lorazepam13107-083TabletGeneric drugs (ANDA)February 1, 2021
Oxycodone Hydrochloride Oral Solution13107-262SolutionGeneric drugs (ANDA)January 27, 2020
Oxycodone Hydrochloride Oral Solution13107-261SolutionGeneric drugs (ANDA)January 27, 2020
Amphetamine Sulfate13107-260TabletGeneric drugs (ANDA)January 31, 2019
Amphetamine Sulfate13107-259TabletGeneric drugs (ANDA)January 31, 2019
Butalbital, Acetaminophen and Caffeine13107-075CapsuleGeneric drugs (ANDA)April 26, 2017
Methylphenidate Hydrochloride13107-382TabletGeneric drugs (ANDA)April 11, 2017
Methylphenidate Hydrochloride13107-381TabletGeneric drugs (ANDA)April 11, 2017
Methylphenidate Hydrochloride13107-380TabletGeneric drugs (ANDA)April 11, 2017
Phentermine13107-106CapsuleGeneric drugs (ANDA)March 20, 2017
Phentermine13107-105CapsuleGeneric drugs (ANDA)March 20, 2017
Hydrocodone Bitartrate and Ibuprofen13107-004Tablet, film coatedGeneric drugs (ANDA)June 2, 2016
Hydromorphone hydrochloride13107-109TabletGeneric drugs (ANDA)May 17, 2016
Hydromorphone hydrochloride13107-108TabletGeneric drugs (ANDA)May 17, 2016

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.